Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review

Parkinson’s disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and disability. PD is caused by a loss of dopaminergic, cholinergic, serotonergic, and noradrenergic neurons in the central nervous system (CNS), and peripherally; the syndromic parkinsonism symptoms...

Full description

Bibliographic Details
Main Authors:	Amnon A. Berger, Ariel Winnick, Alexandra Welschmeyer, Alicia Kaneb, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Omar Viswanath, Ivan Urits
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Neurology International
Subjects:	parkinsonism levodopa carbidopa neurodegenerative catechol-o-methyl transferase (COMT)
Online Access:	https://www.mdpi.com/2035-8377/12/3/17

Similar Items

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
by: Rajesh Pahwa, et al.
Published: (2023-01-01)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

Decreased hepatic enzymes reflect the decreased vitamin B6 levels in Parkinson's disease patients
by: Kensuke Ikenaka, et al.
Published: (2024-02-01)

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
by: Frank C. Church
Published: (2021-04-01)

Effect of daidzein on Parkinson disease induced by reserpine in rats
by: Radha Goel, et al.
Published: (2020-04-01)

Lo Nuevo ante la Enfermedad de Parkinson
by: Juan Mendoza Vega
Published: (1990-12-01)

Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
by: Noriyuki Miyaue, et al.
Published: (2022-07-01)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016-01-01)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
by: Daniël van Poppelen, et al.
Published: (2021-06-01)

An updated calculator for determining levodopa-equivalent dose
by: D. Nyholm, et al.
Published: (2021-10-01)

Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel
by: John P. Savaryn, et al.
Published: (2024-04-01)

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
by: Noriyuki Miyaue, et al.
Published: (2023-01-01)

Personalized Medicine Approach in Treating Parkinson’s Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice
by: Helga María Grétarsdóttir, et al.
Published: (2021-07-01)

LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
by: Walaa A. Kamel, et al.
Published: (2020-09-01)

Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients
by: Szász JA, et al.
Published: (2019-11-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Assessing the Neurotoxicity of a Sub-Optimal Dose of Rotenone in Zebrafish (<i>Danio rerio</i>) and the Possible Neuroactive Potential of Valproic Acid, Combination of Levodopa and Carbidopa, and Lactic Acid Bacteria Strains
by: Ovidiu-Dumitru Ilie, et al.
Published: (2022-10-01)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
by: Angelo Antonini
Published: (2009-05-01)

Association of polymorphic marker Val158Met of COMT gene with depression in an open population 25–44 years old (WHO international program MONICA, epidemiological study)
by: V. V. Gafarov, et al.
Published: (2021-04-01)

An investigation of the COMT gene Val158Met polymorphism in patients admitted to the emergency department because of synthetic cannabinoid use
by: Nennicioglu Y, et al.
Published: (2020-08-01)

Exploring Parkinson’s disease: A question and answer-based approach
by: Philippe Rizek, et al.
Published: (2018-01-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
by: Victor S.C. Fung, et al.
Published: (2024-01-01)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
by: Peter LeWitt, et al.
Published: (2023-01-01)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
by: Sten-Magnus Aquilonius, et al.
Published: (2017-04-01)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
by: Peter A. LeWitt, et al.
Published: (2022-11-01)

Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
by: D. Santos-García, et al.
Published: (2021-03-01)

The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study
by: Kanefumi Yamashita, et al.
Published: (2021-06-01)

LEVODOPA PLUS CARBIDOPA: IS IT EFFECTIVE IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY MANAGEMENT?
by: H GHANBARI, et al.
Published: (2000-03-01)

The inconsistent mediating effect of catechol O methyl transferase Val158Met polymorphism on the sex difference of cognitive impairment in schizophrenia patients
by: Hang Xu, et al.
Published: (2022-09-01)

Playing nice: A multi-methodological study on the effects of social conformity on memory
by: Lorena eDeuker, et al.
Published: (2013-03-01)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
by: Daniel D Truong
Published: (2009-03-01)

Dyskinesia and Pain in Advanced Parkinson’s Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study
by: Eric Freire-Alvarez, et al.
Published: (2024-02-01)

Quantitative Colorimetric Sensing of Carbidopa in Anti-Parkinson Drugs Based on Selective Reaction with Indole-3-Carbaldehyde
by: Pasquale Palladino, et al.
Published: (2023-11-01)

Migration of a Percutaneous Endoscopic Gastrojejunostomy Tube into the Colon with Small Intestinal Telescoping
by: Shinya Taki, et al.
Published: (2019-11-01)

A case of carbidopa/levodopa associated colitis mimicking inflammatory bowel disease
by: Michael J. Steel, et al.
Published: (2022-06-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
by: Saki Oshiro, et al.
Published: (2021-12-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)